Ed Mathers

Ed Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of multiple innovative biotechnology companies, including among others: Ra Pharmaceuticals (NASDAQ:RARX – Chairman), Rhythm Pharmaceuticals (NASDAQ:RYTM), Synlogic (NASDAQ:SYBX), ObsEva (NASDAQ:OBSV), and Liquidia Technologies (NASDAQ: LQDA).

Previously he was a board member of Lumena (sold to Shire), Ziarco (sold to Novartis), Motus Therapeutics (sold to Allergan), Plexxikon (sold to Daiichi Sankyo), MedImmune, LLC, and the Biotechnology Industry Organization (BIO).